THRIVE Pilot
THRIVE Pilot Trial — ACC.26 Late-Breaking Clinical Trial
Presented by Oluwabunmi Ogungbe — Johns Hopkins School of Nursing
Subspecialty: Hypertension
Published in ACC.26 Late-Breaking
Key Result
Late-breaking results from the THRIVE Pilot trial presented at ACC.26.
What did this trial find?
The THRIVE Pilot trial is a Food-is-Medicine randomized controlled trial involving 80 Black and Hispanic adults with hypertension in Maryland, testing a culturally tailored intervention combining produce prescriptions, personalized dietitian coaching, and community co-designed messaging against standard produce delivery. Presented as a late-breaking clinical trial at ACC.26, the study found significant blood pressure reductions in the intervention group, with effects doubling among those with stronger DASH diet adherence. There is limited outside expert commentary available, with coverage primarily featuring the lead author.
Why does this trial matter?
Mostly straightforward coverage. 26 presentation. No editorials, outside expert commentary, or critical/cautious reactions were found. The trial is a small pilot (N=80) focused on feasibility and implementation of a food-is-medicine intervention, generating limited debate.
Study Design
Pilot trial
Clinical Implications
Full results presented at ACC.26.
Abstract
The THRIVE Pilot trial was presented as a late-breaking clinical trial at ACC.26 in New Orleans.